1,442
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Optimal timing to retrieve oocytes for fertility preservation in patients with acute myeloid leukemia: two cases of controlled ovarian stimulation using DuoStim with a literature review

, , , , , , , , , & show all
Article: 2217262 | Received 27 Sep 2022, Accepted 18 May 2023, Published online: 04 Jun 2023

References

  • Ye R, Tomlinson B, de Lima M, et al. Timing embryo preservation for a patient with high-risk newly diagnosed acute myeloid leukemia. Case Rep Hematol. 2018;2018:1.
  • Hanne S, Cvancarova M, Møller B, et al. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129(5):1225–4.
  • Lee SJ, Schover LR, Partridge AH, et al. American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–2931.
  • The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol. 1998;103(1):100–109.
  • Kuang Y, Chen Q, Hong Q, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (shanghai protocol). Reprod Biomed Online. 2014;29(6):684–691.
  • Vaiarelli A, Cimadomo D, Petriglia C, et al. DuoStim – a reproducible strategy to obtain more oocytes and competent embryos in a short time-frame aimed at fertility preservation and IVF purposes. A systematic review. Ups J Med Sci. 2020;125(2):121–130.
  • Sfakianoudis K, Pantos K, Grigoriadis S, et al. What is the true place of a double stimulation and double oocyte retrieval in the same cycle for patients diagnosed with poor ovarian reserve? A systematic review including a meta-analytical approach. J Assist Reprod Genet. 2020;37(1):181–204.
  • Vaiarelli A, Cimadomo D, Conforti A, et al. Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the bologna criteria: a case series. Fertil Steril. 2020;113(1):121–130.
  • Giulia G, Nicole S, Marta C, et al. Folliculogenesis in random start protocols for oocytes cryopreservation: quantitative and qualitative aspects. Reprod Sci. 2022;29(11):3260–3265.
  • Kaitlyn W, Hakan C, Evelyn M, et al. Back-to-back random-start ovarian stimulation prior to chemotherapy to maximize oocyte yield. J Assist Reprod Genet. 2019;36(6):1161–1168.
  • Huang H, Itaya Y, Samejima K, et al. Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation. J Ovarian Res. 2022;15(1):2.
  • Bar-Joseph H, Ben-Aharon I, Rizel S, et al. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Toxicol. 2010;30(4):566–572.
  • Cobo A, Garcia-Velasco JA, Coello A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–764.e8.
  • Demian G, Romina P, Mariana M, et al. How effective are the non-conventional ovarian stimulation protocols in ART? A systematic review and meta-analysis. J Assist Reprod Genet. 2020;37(12):2913–2928.
  • Ito A, Katagiri Y, Tamaki Y, et al. DuoStim: a new option for fertility preservation for a woman with turner syndrome. Gynecol Endocrinol. 2020;36(12):1144–1148.
  • Chung K, Donnez J, Ginsburg E, et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013;99(6):1534–1542.
  • Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection. Hum Reprod Update. 2019;25(6):673–693.
  • Ben-Aharon I, Bar-Joseph H, Tzarfaty G, et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol. 2010;8:20.
  • Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod. 1986;1(2):81–87.
  • McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000;21(2):200–214.
  • Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014;20(3):370–385.
  • Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62.